Mark A Rubin
@marubin1.bsky.social
📤 43
📥 9
📝 6
Precision Oncology researcher in Switzerland with special interest in epigenetics and splicing.
reposted by
Mark A Rubin
ESMO - European Society for Medical Oncology
30 days ago
📣Updated ESMO #ClinicalPracticeGuideline on advanced and metastatic #ProstateCancer: ✅ Substantial advances in castration-sensitive & -resistant prostate cancer ✅ Updated algorithms & recommendations reflecting latest clinical data #ESMOGuidelines
Christopher Sweeney
đź”—
https://ow.ly/E4ov50Yc8e2
0
3
2
🧬 New preprint out! Dilara Akhoundova and team identify AURKA as a synthetic lethal vulnerability in FANCA-deficient cancers using complementary CRISPR and drug screens. 🔗
doi.org/10.64898/202...
#PrecisionOncology
#SyntheticLethality
#FANCA
#AURKA
#CancerGenomics
about 1 month ago
0
1
1
reposted by
Mark A Rubin
American Association for Cancer Research (AACR)
about 2 months ago
Molecular Cancer Research editor Massimo Loda, Franklin W. Huang, Michael C. Haffner, and Irene Paassen discussed "Genomics and Epigenomics" in a plenary session at the AACR Special Conference on Innovations in Prostate Cancer Research and Treatment.
#AACRprostate26
@aacrjournals.bsky.social
0
2
1
Can we help men with hormone-refractory
#ProstateCancer
through personalized epigenetic therapy? Our new study using patient-derived organoids reveals a targetable weakness in a WNT-driven subtype. @genentech.bsky.social
@medfacultyunibe.bsky.social
@unibe.ch
@pmbern.bsky.social
tinyurl.com/2tkn3hwh
about 2 months ago
0
3
2
reposted by
Mark A Rubin
DBMR University Bern
2 months ago
New
@natmed.nature.com
News & Views by
@marubin1.bsky.social
and Dr. Irene Paassen on why
#PrecisionOncology
must go beyond genomics.
@medfacultyunibe.bsky.social
@pmbern.bsky.social
tinyurl.com/2zvdvmy6
0
5
3
reposted by
Mark A Rubin
ESMO - European Society for Medical Oncology
3 months ago
📣 Updated ESMO #ClinicalPracticeGuideline on local & locoregional #ProstateCancer: ✅New imaging modalities: Improved diagnosis, staging & risk stratification ✅Updated algorithms: less over-Tx & fewer side-effects #Oncology #UroOncology #CancerCare #ESMOGuidelines 🔗
https://ow.ly/jwA650XLs1q
1
12
4
Excited to share new preprint on the minor spliceosome in cancer! Targeting U6atac disrupts DNA repair and sensitizes prostate & breast tumors to radiation, cisplatin and PARP inhibitors—even beyond BRCA-mutant .
bit.ly/48RnsI5
#DNARepair
#ProstateCancer
#BreastCancer
#U6atac
@theaacr.bsky.social
3 months ago
0
0
1
Congrats to Jia and Michael and team. This has been a major effort and we are learning so much about lineage plasticity
www.nature.com/articles/s41...
.
loading . . .
NSD2 targeting reverses plasticity and drug resistance in prostate cancer - Nature
Inhibition of the histone methyltransferase NSD2 and the androgen receptor in preclinical models can reverse lineage plasticity to suppress tumour growth and promote cell death in multiple subtypes of...
https://www.nature.com/articles/s41586-025-09727-z
3 months ago
0
0
1
www.nytimes.com/interactive/...
loading . . .
How Trump’s Medical Research Cuts Would Hit Colleges and Hospitals in Every State
Changes to a key funding formula will reduce research grants at hospitals and universities by billions — and may discourage future research.
https://www.nytimes.com/interactive/2025/02/13/upshot/nih-trump-funding-cuts.html?smid=nytcore-ios-share
about 1 year ago
0
0
0
I Used to Run the N.I.H. Here’s What Worries Me.
www.nytimes.com/2025/02/14/o...
loading . . .
Opinion | American Science is Under Attack
The Trump administration hobbles research and endangers the public health.
https://www.nytimes.com/2025/02/14/opinion/trump-public-health-funding-nih.html?smid=bs-share
about 1 year ago
0
1
0
you reached the end!!
feeds!
log in